Principal Investigator

David T.
Awardee Organization

Medical University Of South Carolina
United States

Fiscal Year
Activity Code
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

Medical University of South Carolina NCORP Minority/Underserved Community Site

The Medical University of South Carolina/Hollings Cancer Center (MUSC/HCC) was established as a Minority Underserved site in 2014 to expand and enhance the NCORP trial portfolio by accruing racially/ethnically diverse patients and those from other medically underserved groups into NCORP studies, share expertise and experience on minority recruitment and retention and cultural diversity within the NCORP community, and contribute to the development and implementation of cancer care and cancer delivery research. During the current project period, the MUSC NCORP-MU, which is comprised of two MUSC/HCC sub-affiliates and five community oncology primary affiliates, has made significant contributions to the NCORP program through the effective and efficient accrual of diverse patient populations and leadership that has shaped the scientific agenda for clinical trials, cancer health disparities, and cancer care delivery research. These accomplishments were made possible through a highly invested and transdisciplinary investigative team consisting of Chanita Hughes-Halbert, PhD (Psychiatry & Behavioral Sciences), Marvella E. Ford, PhD (Public Health Sciences), Carolyn D. Britten, MD (Medical Oncology), and David T. Marshall, MD (Radiation Oncology) that has worked hand-inhand with the clinical research operational leaders at the MUSC/HCC to establish and manage a robust clinical research operation to add value to NCORP. This leadership team has also worked collaboratively with other committed clinical and cancer control researchers, oncology care providers, cancer patients, and survivors in our catchment areas to advance all types of cancer research through the NCORP research bases. The MUSC NCORP-MU aims to improve equity and access to clinical research among racial/ethnic minorities and other medically underserved groups in order to improve cancer outcomes, enhance the quality of cancer care delivery, and reduce cancer health disparities within South Carolina and communities across the US.


  • Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Mar 1;36(7):697-703. Epub 2018 Jan 22. PMID: 29356608
  • Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Feb 1;36(4):326-332. Epub 2017 Nov 14. PMID: 29136387
  • Halbert CH, Jefferson MS, Drake R, Lilly M, Savage SJ, Nahhas GJ, Price ST, Loftley AE, Bauer A. Social and clinical determinants of physical activity in prostate cancer survivors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2021 Jan;29(1):459-465. Epub 2020 May 11. PMID: 32394247
  • Ritchie JB, Allen CG, Morrison H, Nichols M, Lauzon SD, Schiffman JD, Hughes Halbert C, Welch BM. Utilization of health information technology among cancer genetic counselors. Molecular genetics & genomic medicine. 2020 Aug;8(8):e1315. Epub 2020 May 28. PMID: 32468681
  • Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, Chiorean EG, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Annals of surgery. 2020 Sep 1;272(3):481-486. PMID: 32740235
  • Tilburt JC, Zahrieh D, Pacyna JE, Petereit DG, Kaur JS, Rapkin BD, Grubb RL 3rd, Chang GJ, Morris MJ, Kovac EZ, Babaian KN, Sloan JA, Basch EM, Peil ES, Dueck AC, Novotny PJ, Paskett ED, Buckner JC, Joyce DD, Montori VM, Frosch DL, Volk RJ, Kim SP. Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer. 2022 Mar 15;128(6):1242-1251. Epub 2021 Dec 10. PMID: 34890060
  • Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S, Zeleznik-Le NJ. Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leukemia research. 2016 Mar;42:68-74. Epub 2016 Jan 15. PMID: 26818573
  • Zhang J, Ye ZW, Townsend DM, Hughes-Halbert C, Tew KD. Racial disparities, cancer and response to oxidative stress. Advances in cancer research. 2019;144:343-383. Epub 2019 Apr 23. PMID: 31349903
  • Press OW, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce AS, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Jun 10;34(17):2020-7. Epub 2016 Apr 11. PMID: 27069074
  • Chiorean EG, Guthrie KA, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 Dec 1;27(23):6314-6322. Epub 2021 Sep 27. PMID: 34580114
  • Ford ME, Magwood G, Brown ET, Cannady K, Gregoski M, Knight KD, Peterson LL, Kramer R, Evans-Knowell A, Turner DP. Disparities in Obesity, Physical Activity Rates, and Breast Cancer Survival. Advances in cancer research. 2017;133:23-50. Epub 2016 Oct 31. PMID: 28052820
  • Herbst RS, Redman MW, Kim ES, Semrad TJ, Bazhenova L, Masters G, Oettel K, Guaglianone P, Reynolds C, Karnad A, Arnold SM, Varella-Garcia M, Moon J, Mack PC, Blanke CD, Hirsch FR, Kelly K, Gandara DR. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. The Lancet. Oncology. 2018 Jan;19(1):101-114. Epub 2017 Nov 20. PMID: 29169877
  • Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, Mrózek K, Carroll AJ, Eisfeld AK, Wang ES, Jacobson S, Kolitz JE, Thakuri M, Sutamtewagul G, Vij R, Stuart RK, Byrd JC, Bloomfield CD, Stone RM, Larson RA. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood advances. 2021 Jul 13;5(13):2775-2787. PMID: 34251414
  • Ben-Josef E, Guthrie KA, El-Khoueiry AB, Corless CL, Zalupski MM, Lowy AM, Thomas CR Jr, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Aug 20;33(24):2617-22. Epub 2015 May 11. PMID: 25964250
  • Flaig TW, Tangen CM, Daneshmand S, Alva A, Lerner SP, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr. A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 May 1;27(9):2435-2441. Epub 2021 Feb 10. PMID: 33568346
  • Halbert CH, Jefferson M, Allen CG, Babatunde OA, Drake R, Angel P, Savage SJ, Frey L, Lilly M, Obi T, Obeid J. Racial Differences in Patient Portal Activation and Research Enrollment Among Patients With Prostate Cancer. JCO clinical cancer informatics. 2021 Jun;5:768-774. PMID: 34328797
  • West HL, Moon J, Wozniak AJ, Mack P, Hirsch FR, Bury MJ, Kwong M, Nguyen DD, Moore DF, Miao J, Redman M, Kelly K, Gandara DR. Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clinical lung cancer. 2018 Jan;19(1):84-92. Epub 2017 Jul 6. PMID: 28801183
  • Allen CG, Ritchie JB, Morrison H, Lauzon SD, Nichols M, Schiffman JD, Hughes Halbert C, Welch BM. A thematic analysis of health information technology use among cancer genetic counselors. Journal of genetic counseling. 2021 Feb;30(1):170-179. Epub 2020 Jul 8. PMID: 32643297
  • Danilov AV, Li H, Press OW, Shapira I, Swinnen LJ, Noy A, Reid E, Smith SM, Friedberg JW. Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leukemia & lymphoma. 2017 Feb;58(2):461-465. Epub 2016 Jul 7. PMID: 27386786
  • Pagel JM, Othus M, Garcia-Manero G, Fang M, Radich JP, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, Savoie ML, Spellman SR, Confer DL, Chell JW, Brown M, Medeiros BC, Sekeres MA, Lin TL, Uy GL, Powell BL, Bayer RL, Larson RA, Stone RM, Claxton D, Essell J, Luger SM, Mohan SR, Moseley A, Erba HP, Appelbaum FR. Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid Leukemia. JCO oncology practice. 2020 Jun;16(6):e464-e475. Epub 2020 Jan 27. PMID: 32048933
  • Halbert CH, McDonald J, Vadaparampil S, Rice L, Jefferson M. Conducting Precision Medicine Research with African Americans. PloS one. 2016 Jul 21;11(7):e0154850. doi: 10.1371/journal.pone.0154850. eCollection 2016. PMID: 27441706
  • Ford ME, Cannady K, Nahhas GJ, Knight KD, Chavis C, Crawford B, Malek AM, Martino E, Frazier S, Gathers A, Lawton C, Cartmell KB, Luque JS. Assessing an intervention to increase knowledge related to cervical cancer and the HPV vaccine. Advances in cancer research. 2020;146:115-137. Epub 2020 Mar 12. PMID: 32241386
  • Cartmell KB, Bonilha HS, Simpson KN, Ford ME, Bryant DC, Alberg AJ. Patient barriers to cancer clinical trial participation and navigator activities to assist. Advances in cancer research. 2020;146:139-166. Epub 2020 Feb 24. PMID: 32241387
  • Ford ME, Bauza CE, Findlay VJ, Turner DP, Abraham LM, Moore LA, Magwood G, Alberg AJ, Gaymon K, Knight KD, Hilton E, Malek AM, Kramer RM, Peterson LL, Gregoski MJ, Bolick S, Hurley D, Mosley C, Hazelton TR, Burshell DR, Nogueira L, Mack F, Brown ET, Salley JD, Whitfield KE, Esnaola NF, Cunningham JE. BMI, physical activity, and breast cancer subtype in white, black, and Sea Island breast cancer survivors. Advances in cancer research. 2020;146:83-102. Epub 2020 Mar 12. PMID: 32241393
  • Bauer AG, Jefferson M, Nahhas GJ, Savage S, Drake R, Lilly M, Ambrose L, Caulder S, Mahvi D, Hughes Halbert C. Financial toxicity and strain among men receiving prostate cancer care in an equal access healthcare system. Cancer medicine. 2020 Dec;9(23):8765-8771. Epub 2020 Oct 17. PMID: 33070458
  • Meystre SM, Heider PM, Kim Y, Aruch DB, Britten CD. Automatic trial eligibility surveillance based on unstructured clinical data. International journal of medical informatics. 2019 Sep;129:13-19. Epub 2019 May 23. PMID: 31445247
  • Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, Litzow MR, Komrokji RS, Erba HP, Appelbaum FR. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood advances. 2020 Apr 28;4(8):1683-1689. PMID: 32330241
  • Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. Blood advances. 2016 Dec 27;1(3):250-259. PMID: 29046900